Prostate-specific membrane antigen (PSMA) and somatostatin receptor (SSTR)–targeted PET imaging are recognized as diagnostic tools in mRCC patients beyond their classical use in prostate cancer and neuroendocrine tumors, respectively [16–21]. This evidence concerns the gene FOLH1 and prostate cancer.